Key Publications

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung CancerPatients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer